Epigenetic repression of regulator of G-protein signaling 2 by ubiquitin-like with PHD and ring-finger domain 1 promotes bladder cancer progression

FEBS Journal

Volumn 282, Issue 1, 2015, Pages 174-182

  Ying, Liang ^a   Lin, Jun ^b   Qiu, Feng ^a   Cao, Ming ^a   Chen, Haige ^a   Liu, Zhihong ^c   Huang, Yiran ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

bladder cancer; cell proliferation; methylation; regulator of G protein signaling 2; ubiquitin like with PHD and ring finger domain 1

Indexed keywords

RGS2 PROTEIN; RING FINGER PROTEIN; UBIQUITIN LIKE WITH PHD AND RING FINGER DOMAIN 1; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; MESSENGER RNA; RGS PROTEIN; RGS2 PROTEIN, HUMAN; RNA; UHRF1 PROTEIN, HUMAN;

AGED; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; RGS2 GENE; BLADDER TUMOR; CASE CONTROL STUDY; CPG ISLAND; DISEASE COURSE; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

AGED; CASE-CONTROL STUDIES; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RGS PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; URINARY BLADDER NEOPLASMS;

EID: 84920781476     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13116     Document Type: Article

References (25)

1. Siegel R, Naishadham D, &, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63, 11-30.
2. Gierth M, &, Burger M, (2013) Bladder cancer: progress in defining progression in NMIBC. Nat Rev Urol 10, 684-685.
3. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, &, Edwards BK, (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541-552.
4. Parkin DM, (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl, 218, 12-20.
5. Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, Liu Y, &, Qiu F, (2013) Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol BioSyst 9, 407-411.
6. Kandimalla R, van Tilborg AA, &, Zwarthoff EC, (2013) DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 10, 327-335.
7. Chiam K, Ricciardelli C, &, Bianco-Miotto T, (2014) Epigenetic biomarkers in prostate cancer: current and future uses. Cancer Lett 342, 248-256.
8. Liu X, Gao Q, Li P, Zhao Q, Zhang J, Li J, Koseki H, &, Wong J, (2013) UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. Nat Commun 4, 1563.
9. Law JA, &, Jacobsen SE, (2010) Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet 11, 204-220.
10. Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, et al,. (2014) UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 25, 196-209.
11. Sabatino L, Fucci A, Pancione M, Carafa V, Nebbioso A, Pistore C, Babbio F, Votino C, Laudanna C, Ceccarelli M, et al,. (2012) UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene 31, 5061-5072.
12. Sethakorn N, &, Dulin NO, (2013) RGS expression in cancer: oncomining the cancer microarray data. J Recept Signal Transduct Res 33, 166-171.
13. Kehrl JH, &, Sinnarajah S, (2002) RGS2: a multifunctional regulator of G-protein signaling. Int J Biochem Cell Biol 34, 432-438.
14. Jiang Z, Wang Z, Xu Y, Wang B, Huang W, &, Cai S, (2010) Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer. Biosci Rep 30, 383-390.
15. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, &, Tu Y, (2006) Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25, 3719-3734.
16. Wolff DW, Xie Y, Deng C, Gatalica Z, Yang M, Wang B, Wang J, Lin MF, Abel PW, &, Tu Y, (2012) Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer 130, 1521-1531.
17. Karouzakis E, Rengel Y, Jungel A, Kolling C, Gay RE, Michel BA, Tak PP, Gay S, Neidhart M, &, Ospelt C, (2011) DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun 12, 643-652.
18. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, &, Hamamoto R, (2009) UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 101, 98-105.
19. Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, Zou Y, &, Qin HL, (2012) UHRF1 promotes cell growth and metastasis through repression of p16(ink(4)a) in colorectal cancer. Ann Surg Oncol 19, 2753-2762.
20. Zhong H, &, Neubig RR, (2001) Regulator of G protein signaling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 297, 837-845.
21. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, Liotta LA, Fisher R, &, Wu X, (2004) A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 64, 6820-6826.
22. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, &, Largaespada DA, (2005) Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436, 272-276.
23. Schwable J, Choudhary C, Thiede C, Tickenbrock L, Sargin B, Steur C, Rehage M, Rudat A, Brandts C, Berdel WE, et al,. (2005) RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 105, 2107-2114.
24. Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, &, Bronner C, (2011) Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 30, 41.
25. Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Durst M, Kristiansen G, Wild PJ, Hartmann A, et al,. (2008) The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene 27, 865-876.